Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia
Journal of Cachexia, Sarcopenia and Muscle · 2023
DOI: 10.1002/jcsm.13191 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2023. Verfasst von Megan Herodes und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gerontology and Geriatric Medicine, School of Medicine, University of Washington, Seattle, WA, USA. Hauptthemen laut MEDLINE: Cachexia, Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, BLRD VA, RRD VA.
Abstract (Originalsprache)
Background
Cancer cachexia is associated with reduced body weight, appetite and quality of life (QOL) with no approved treatments. Growth hormone secretagogues like macimorelin have potential to mitigate these effects.
Methods
This pilot study assessed the safety and efficacy of macimorelin for 1 week. Efficacy was defined a priori as 1‐week change in body weight (≥0.8 kg), plasma insulin‐like growth factor (IGF)‐1 (≥50 ng/mL) or QOL (≥15%). Secondary outcomes included food intake, appetite, functional performance, energy expenditure and safety laboratory parameters. Patients with cancer cachexia were randomized to 0.5 or 1.0 mg/kg macimorelin or placebo; outcomes were assessed non‐parametrically.
Results
Participants receiving at least one of either macimorelin dose were combined ( N = 10; 100% male; median age = 65.50 ± 2.12) and compared with placebo ( N = 5; 80% male; median age = 68.00 ± 6.19). Efficacy criteria achieved: body weight (macimorelin N = 2; placebo N = 0; P = 0.92); IGF‐1 (macimorelin N = 0; placebo N = 0); QOL by Anderson Symptom Assessment Scale (macimorelin N = 4; placebo N = 1; P = 1.00) or Functional Assessment of Chronic Illness Therapy‐Fatigue (FACIT‐F; macimorelin N = 3; placebo N = 0; P = 0.50). No related serious or non‐serious adverse events were reported. In macimorelin recipients, change in FACIT‐F was directly associated with change in body weight ( r = 0.92, P = 0.001), IGF‐1 ( r = 0.80, P = 0.01), and caloric intake ( r = 0.83, P = 0.005), and inversely associated with change in energy expenditure ( r = −0.67, P = 0.05).
Conclusions
Daily oral macimorelin for 1 week was safe and numerically improved body weight and QOL in patients with cancer cachexia compared with placebo. Longer term administration should be evaluated for mitigation of cancer‐induced reductions in body weight, appetite and QOL in larger studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gerontology and Geriatric Medicine, School of Medicine, University of Washington, Seattle, WA, USA.
- Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA.
- Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, WA, USA.
- Hospital and Specialty Medicine, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA.
- Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
- Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
ORCID-Profile: Megan Herodes, Jose M Garcia
Förderung
- NIDDK NIH HHS
- BLRD VA
- RRD VA
- NIAMS NIH HHS
- CSRD VA
- NIA NIH HHS
- NCI NIH HHS
- U.S. Department of Veterans Affairs
Zitieren
APA
Herodes, M., Anderson, L. J., Shober, S., Schur, E. A., Graf, S. A., Ammer, N., Salas, R., Marcelli, M., & Garcia, J. M. (2023). Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.13191
Vancouver
Herodes M, Anderson LJ, Shober S, Schur EA, Graf SA, Ammer N, et al. Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle. 2023. doi:10.1002/jcsm.13191
BibTeX
@article{Herodes2023,
author = {Herodes, Megan and Anderson, Lindsey J and Shober, Samuel and Schur, Ellen A and Graf, Solomon A and Ammer, Nicola and Salas, Ramiro and Marcelli, Marco and Garcia, Jose M},
title = {Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2023},
doi = {10.1002/jcsm.13191}
}
EUVIMED